Side-by-side · Research reference
SemaglutidevsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedVerified15/53 cited
BFDA-ApprovedVerified14/45 cited
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Semaglutide
Tirzepatide
Primary target
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
Glucose-dependent insulin release preserves physiological feedback
Origin
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
Semaglutide
Tirzepatide
Standard dose (weight, Wegovy)
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
—
Frequency
Once weekly, same day each week
—
Titration schedule
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
Evidence basis
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
Indefinite for chronic indication
Discontinuation results in weight regain.
Indefinite for chronic indication
Reconstitution
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
Any time of day, with or without food
Once weekly, any time of day
Half-life
~7 days (168 h)WEGOVY (semaglutide) injection 2021
~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
04Side Effects & Safety
Parameter
Semaglutide
Tirzepatide
GI symptoms
Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021
Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022
Injection site reaction
Mild erythema, pruritus
Mild erythema, pruritus
Pancreatitis risk
Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021
Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
Increased cholelithiasis
Increased cholelithiasis
Heart rate
Modest ↑ resting HR (~2-4 bpm)
—
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
Semaglutide
Tirzepatide
1. Reconstitution / device
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Once weekly, same day. Day can be changed if ≥2 days separate doses.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Needle
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
Pen-supplied. Research vial: 27–31G insulin syringe.
06Stack Synergy
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)
Tirzepatide
— no documented stacks